Modular basis for potent SARS-CoV-2 neutralization by a prevalent VH1-2-derived antibody class
Open accessPublished version of a preprint
The DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
Abstract
SUMMARY Antibodies with heavy chains that derive from the VH1-2 gene constitute some of the most potent SARS-CoV-2-neutralizing antibodies yet identified. To provide insight into whether these genetic similarities inform common modes of recognition, we determined structures of the SARS-CoV-2 spike in complex with three VH1-2-derived antibodies: 2-15, 2-43, and H4. All three utilized VH1-2-encoded motifs to recognize the receptor-binding domain (RBD), with heavy chain N53I enhancing binding and light chain tyrosines recognizing F486 RBD . Despite these similarities, class members bound both RBD-up and -down conformations of the spike, with a subset of antibodies utilizing elongated CDRH3s to recognize glycan N 343 on a neighboring RBD – a quaternary interaction accommodated by an increase in RBD separation of up to 12 Å. The VH1-2-antibody class thus utilizes modular recognition encoded by modular genetic elements to effect potent neutralization, with VH-gene component specifying recognition of RBD and CDRH3 component specifying quaternary interactions. Highlights Determine structures of VH1-2-derived antibodies 2-43, 2-15, and H4 in complex with SARS-CoV-2 spike Define a multi-donor VH1-2-antibody class with modular components for RBD and quaternary recognition Reveal structural basis of RBD-up and RBD-down recognition within the class Show somatic hypermutations and avidity to be critical for potency Delineate changes in spike conformation induced by CDRH3-mediated quaternary recognition
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Towards automated crystallographic structure refinement with phenix.refine
Afonine, P. V., Grosse-Kunstleve, R. W., Echols, N., Headd, J. J., Moriarty, N. W., Mustyakimov, M., Terwilliger, T. C., Urzhumtsev, A., Zwart, P. H., & Adams, P. D. (2012) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444912001308 · Cited by 5,511 · cited 1×
“, 2010) was alternated with refinement using Phenix refine (Afonine et al., 2012) and PDB-REDO (Joosten et al.”
UCSF ChimeraX: Meeting modern challenges in visualization and analysis
Goddard, T. D., Huang, C. C., Meng, E. C., Pettersen, E. F., Couch, G. S., Morris, J. H., & Ferrin, T. E. (2018) · Protein Science · doi:10.1002/pro.3235 · Cited by 5,267
Structural and Functional Basis of SARS-CoV-2 Entry by Using Human ACE2
Wang, Q., Zhang, Y., Wu, L., Niu, S., Song, C., Zhang, Z., Lu, G., Qiao, C., Hu, Y., Yuen, K.-Y., et al. (2020) · Cell · doi:10.1016/j.cell.2020.03.045 · Cited by 2,892
Estimated transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in England
Davies, N. G., Abbott, S., Barnard, R. C., Jarvis, C. I., Kucharski, A. J., Munday, J. D., Pearson, C. A. B., Russell, T. W., Tully, D. C., Washburne, A. D., et al. (2020) · doi:10.1101/2020.12.24.20248822 · Cited by 2,557
Tegally, H., Wilkinson, E., Giovanetti, M., Iranzadeh, A., Fonseca, V., Giandhari, J., Doolabh, D., Pillay, S., San, E. J., Msomi, N., et al. (2020) · doi:10.1101/2020.12.21.20248640 · Cited by 2,535 · cited 1×
“429) with transmission rates dramatically higher than that of preexisting strains (Davies et al., 2021; Tegally et al., 2020).”
Detection of a SARS-CoV-2 variant of concern in South Africa
Tegally, H., Wilkinson, E., Giovanetti, M., Iranzadeh, A., Fonseca, V., Giandhari, J., Doolabh, D., Pillay, S., San, E. J., Msomi, N., et al. (2021) · Nature · doi:10.1038/s41586-021-03402-9 · Cited by 2,510
Antibody Resistance of SARS-CoV-2 Variants B.1.351 and B.1.1.7
Wang, P., Nair, M. S., Liu, L., Iketani, S., Luo, Y., Guo, Y., Wang, M., Yu, J., Zhang, B., Kwong, P. D., et al. (2021) · doi:10.1101/2021.01.25.428137 · Cited by 2,328
Self-citationAntibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7
Wang, P., Nair, M. S., Liu, L., Iketani, S., Luo, Y., Guo, Y., Wang, M., Yu, J., Zhang, B., Kwong, P. D., et al. (2021) · Nature · doi:10.1038/s41586-021-03398-2 · Cited by 2,312
Self-citationClustal Omega for making accurate alignments of many protein sequences
Sievers, F., & Higgins, D. G. (2018) · Protein Science · doi:10.1002/pro.3290 · Cited by 2,137
Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody
Pinto, D., Park, Y.-J., Beltramello, M., Walls, A. C., Tortorici, M. A., Bianchi, S., Jaconi, S., Culap, K., Zatta, F., De Marco, A., et al. (2020) · Nature · doi:10.1038/s41586-020-2349-y · Cited by 1,885
Convergent Antibody Responses to SARS-CoV-2 in Convalescent Individuals
Robbiani, D. F., Gaebler, C., Muecksch, F., Lorenzi, J. C. C., Wang, Z., Cho, A., Agudelo, M., Barnes, C. O., Gazumyan, A., Finkin, S., et al. (2020) · Nature · doi:10.1038/s41586-020-2456-9 · Cited by 1,853
Structural and functional analysis of a potent sarbecovirus neutralizing antibody
Pinto, D., Park, Y.-J., Beltramello, M., Walls, A. C., Tortorici, M. A., Bianchi, S., Jaconi, S., Culap, K., Zatta, F., De Marco, A., et al. (2020) · doi:10.1101/2020.04.07.023903 · Cited by 1,752
Human neutralizing antibodies elicited by SARS-CoV-2 infection
Ju, B., Zhang, Q., Ge, J., Wang, R., Sun, J., Ge, X., Yu, J., Shan, S., Zhou, B., Song, S., et al. (2020) · Nature · doi:10.1038/s41586-020-2380-z · Cited by 1,667
Self-citationSARS-CoV-2 neutralizing antibody structures inform therapeutic strategies
Barnes, C. O., Jette, C. A., Abernathy, M. E., Dam, K.-M. A., Esswein, S. R., Gristick, H. B., Malyutin, A. G., Sharaf, N. G., Huey-Tubman, K. E., Lee, Y. E., et al. (2020) · Nature · doi:10.1038/s41586-020-2852-1 · Cited by 1,599
Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike
Liu, L., Wang, P., Nair, M. S., Yu, J., Rapp, M., Wang, Q., Luo, Y., Chan, J. F.-W., Sahi, V., Figueroa, A., et al. (2020) · Nature · doi:10.1038/s41586-020-2571-7 · Cited by 1,349
Self-citationA human neutralizing antibody targets the receptor-binding site of SARS-CoV-2
Shi, R., Shan, C., Duan, X., Chen, Z., Liu, P., Song, J., Song, T., Bi, X., Han, C., Wu, L., et al. (2020) · Nature · doi:10.1038/s41586-020-2381-y · Cited by 1,286
Self-citationSARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with Covid-19
Chen, P., Nirula, A., Heller, B., Gottlieb, R. L., Boscia, J., Morris, J., Huhn, G., Cardona, J., Mocherla, B., Stosor, V., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2029849 · Cited by 1,282
Rogers, T. F., Zhao, F., Huang, D., Beutler, N., Burns, A., He, W.-T., Limbo, O., Smith, C., Song, G., Woehl, J., et al. (2020) · Science · doi:10.1126/science.abc7520 · Cited by 1,230
Distinct conformational states of SARS-CoV-2 spike protein
Cai, Y., Zhang, J., Xiao, T., Peng, H., Sterling, S. M., Walsh, R. M., Rawson, S., Rits-Volloch, S., & Chen, B. (2020) · Science · doi:10.1126/science.abd4251 · Cited by 1,221
Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail
Hansen, J., Baum, A., Pascal, K. E., Russo, V., Giordano, S., Wloga, E., Fulton, B. O., Yan, Y., Koon, K., Patel, K., et al. (2020) · Science · doi:10.1126/science.abd0827 · Cited by 1,210
Self-citationPotent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability
Brouwer, P. J. M., Caniels, T. G., van der Straten, K., Snitselaar, J. L., Aldon, Y., Bangaru, S., Torres, J. L., Okba, N. M. A., Claireaux, M., Kerster, G., et al. (2020) · Science · doi:10.1126/science.abc5902 · Cited by 1,140
Potently neutralizing and protective human antibodies against SARS-CoV-2
Zost, S. J., Gilchuk, P., Case, J. B., Binshtein, E., Chen, R. E., Nkolola, J. P., Schäfer, A., Reidy, J. X., Trivette, A., Nargi, R. S., et al. (2020) · Nature · doi:10.1038/s41586-020-2548-6 · Cited by 1,041
Increased mortality in community-tested cases of SARS-CoV-2 lineage B.1.1.7
CMMID COVID-19 Working Group, Davies, N. G., Jarvis, C. I., Edmunds, W. J., Jewell, N. P., Diaz-Ordaz, K., & Keogh, R. H. (2021) · Nature · doi:10.1038/s41586-021-03426-1 · Cited by 921
EMRinger: side chain–directed model and map validation for 3D cryo-electron microscopy
Barad, B. A., Echols, N., Wang, R. Y.-R., Cheng, Y., DiMaio, F., Adams, P. D., & Fraser, J. S. (2015) · Nature Methods · doi:10.1038/nmeth.3541 · Cited by 886
Barnes, C. O., West, A. P., Huey-Tubman, K. E., Hoffmann, M. A. G., Sharaf, N. G., Hoffman, P. R., Koranda, N., Gristick, H. B., Gaebler, C., Muecksch, F., et al. (2020) · Cell · doi:10.1016/j.cell.2020.06.025 · Cited by 795
Rational HIV Immunogen Design to Target Specific Germline B Cell Receptors
Jardine, J., Julien, J.-P., Menis, S., Ota, T., Kalyuzhniy, O., McGuire, A., Sok, D., Huang, P.-S., MacPherson, S., Jones, M., et al. (2013) · Science · doi:10.1126/science.1234150 · Cited by 770
Structural basis of a shared antibody response to SARS-CoV-2
Yuan, M., Liu, H., Wu, N. C., Lee, C.-C. D., Zhu, X., Zhao, F., Huang, D., Yu, W., Hua, Y., Tien, H., et al. (2020) · Science · doi:10.1126/science.abd2321 · Cited by 589
Wrobel, A. G., Benton, D. J., Xu, P., Roustan, C., Martin, S. R., Rosenthal, P. B., Skehel, J. J., & Gamblin, S. J. (2020) · Nature Structural & Molecular Biology · doi:10.1038/s41594-020-0468-7 · Cited by 544
Identification of SARS-CoV-2 inhibitors using lung and colonic organoids
Han, Y., Duan, X., Yang, L., Nilsson-Payant, B. E., Wang, P., Duan, F., Tang, X., Yaron, T. M., Zhang, T., Uhl, S., et al. (2021) · Nature · doi:10.1038/s41586-020-2901-9 · Cited by 530 · cited 1×
“Pseudovirus neutralization assays Recombinant Indiana VSV (rVSV) expressing SARS-CoV-2 spikes were generated as previously described (Han et al., 2021; Liu et al., 2020b).”
Self-citationUltrapotent human antibodies protect against SARS-CoV-2 challenge via multiple mechanisms
Tortorici, M. A., Beltramello, M., Lempp, F. A., Pinto, D., Dang, H. V., Rosen, L. E., McCallum, M., Bowen, J., Minola, A., Jaconi, S., et al. (2020) · Science · doi:10.1126/science.abe3354 · Cited by 510
Kreye, J., Reincke, S. M., Kornau, H.-C., Sánchez-Sendin, E., Corman, V. M., Liu, H., Yuan, M., Wu, N. C., Zhu, X., Lee, C.-C. D., et al. (2020) · Cell · doi:10.1016/j.cell.2020.09.049 · Cited by 347
Vaccine-Induced Antibodies that Neutralize Group 1 and Group 2 Influenza A Viruses
Joyce, M. G., Wheatley, A. K., Thomas, P. V., Chuang, G.-Y., Soto, C., Bailer, R. T., Druz, A., Georgiev, I. S., Gillespie, R. A., Kanekiyo, M., et al. (2016) · Cell · doi:10.1016/j.cell.2016.06.043 · Cited by 333
Self-citationA thermostable, closed SARS-CoV-2 spike protein trimer
Xiong, X., Qu, K., Ciazynska, K. A., Hosmillo, M., Carter, A. P., Ebrahimi, S., Ke, Z., Scheres, S. H. W., Bergamaschi, L., Grice, G. L., et al. (2020) · Nature Structural & Molecular Biology · doi:10.1038/s41594-020-0478-5 · Cited by 313
ABodyBuilder: automated antibody structure prediction with data-driven accuracy estimation
Leem, J., Dunbar, J., Georges, G., Shi, J., & Deane, C. M. (2016) · mAbs · doi:10.1080/19420862.2016.1205773 · Cited by 238
Research works printed but not linked: 56
- Adams, 2004, Recent developments in the PHENIX software for automated crystallographic structure determination, J. Synchrotron Radiat., 11, 53, 10.1107/S0909049503024130 · DOI · Paper page
- Adams, 2010, PHENIX: a comprehensive Python-based system for macromolecular structure solution, Acta Crystallogr. D Biol. Crystallogr., 66, 213, 10.1107/S0907444909052925 · DOI · Paper page
- Bangaru, 2020, Structural analysis of full-length SARS-CoV-2 spike protein from an advanced vaccine candidate, Science, 370, 1089, 10.1126/science.abe1502 · DOI · Paper page
- Brochet, 2008, IMGT/V-QUEST: the highly customized and integrated system for IG and TR standardized V-J and V-D-J sequence analysis, Nucleic Acids Res., 36, 10.1093/nar/gkn316 · DOI · Paper page
- Cao, 2020, Potent Neutralizing Antibodies against SARS-CoV-2 Identified by High-Throughput Single-Cell Sequencing of Convalescent Patients’ B Cells, Cell, 182, 73, 10.1016/j.cell.2020.05.025 · DOI · Paper page
- Chen, 2010, MolProbity: all-atom structure validation for macromolecular crystallography, Acta Crystallogr. D Biol. Crystallogr., 66, 12, 10.1107/S0907444909042073 · DOI · Paper page
- 1994, The CCP4 suite: programs for protein crystallography, Acta Crystallogr. D Biol. Crystallogr., 50, 760, 10.1107/S0907444994003112 · DOI · Paper page
- Croll, 2018, ISOLDE: a physically realistic environment for model building into low-resolution electron-density maps, Acta Crystallogr. D Struct. Biol., 74, 519, 10.1107/S2059798318002425 · DOI · Paper page
- Davies, 2021, Estimated transmissibility and severity of novel SARS-CoV-2 variant of concern 202012/01 in England, medRxiv
- Davis, 2004, MOLPROBITY: structure validation and all-atom contact analysis for nucleic acids and their complexes, Nucleic Acids Res., 32, 10.1093/nar/gkh398 · DOI · Paper page
- Diemert, 2018, A phase I trial to evaluate the safety and immunogenicity of eOD-GT8 60mer vaccine, adjuvanted, ClinicalTrials.gov
- Dong, 2020, An interactive web-based dashboard to track COVID-19 in real time, Lancet Infect. Dis., 20, 533, 10.1016/S1473-3099(20)30120-1 · DOI · Paper page
- Du, 2020, Structurally Resolved SARS-CoV-2 Antibody Shows High Efficacy in Severely Infected Hamsters and Provides a Potent Cocktail Pairing Strategy, Cell, 183, 1013, 10.1016/j.cell.2020.09.035 · DOI · Paper page
- Edgar, 2004, MUSCLE: multiple sequence alignment with high accuracy and high throughput, Nucleic Acids Res., 32, 1792, 10.1093/nar/gkh340 · DOI · Paper page
- Ehrhardt, 2019, Polyclonal and convergent antibody response to Ebola virus vaccine rVSV-ZEBOV, Nat. Med., 25, 1589, 10.1038/s41591-019-0602-4 · DOI
- Emsley, 2004, Coot: model-building tools for molecular graphics, Acta Crystallogr. D Biol. Crystallogr., 60, 2126, 10.1107/S0907444904019158 · DOI · Paper page
- Emsley, 2010, Features and development of Coot, Acta Crystallogr. D Biol. Crystallogr., 66, 486, 10.1107/S0907444910007493 · DOI · Paper page
- Evans, 2006, Scaling and assessment of data quality, Acta Crystallogr. D Biol. Crystallogr., 62, 72, 10.1107/S0907444905036693 · DOI · Paper page
- Haynes, 2012, B-cell-lineage immunogen design in vaccine development with HIV-1 as a case study, Nat. Biotechnol., 30, 423, 10.1038/nbt.2197 · DOI · Paper page
- Henderson, 2020, Controlling the SARS-CoV-2 spike glycoprotein conformation, Nat. Struct. Mol. Biol., 27, 925, 10.1038/s41594-020-0479-4 · DOI · Paper page
- Herrera, 2020, Characterization of the SARS-CoV-2 S Protein: Biophysical, Biochemical, Structural, and Antigenic Analysis, ACS Omega, 6, 85, 10.1021/acsomega.0c03512 · DOI
- Hoffmann, 2020, SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor, Cell, 181, 271, 10.1016/j.cell.2020.02.052 · DOI · Paper page
- Huo, 2020, Neutralization of SARS-CoV-2 by Destruction of the Prefusion Spike, Cell Host Microbe, 28, 445, 10.1016/j.chom.2020.06.010 · DOI · Paper page
- Hurlburt, 2020, Structural basis for potent neutralization of SARS-CoV-2 and role of antibody affinity maturation, Nat. Commun., 11, 5413, 10.1038/s41467-020-19231-9 · DOI · Paper page
- Imkeller, 2018, Antihomotypic affinity maturation improves human B cell responses against a repetitive epitope, Science, 360, 1358, 10.1126/science.aar5304 · DOI
- Joosten, 2014, The PDB_REDO server for macromolecular structure model optimization, IUCrJ, 1, 213, 10.1107/S2052252514009324 · DOI · Paper page
- Kabsch, 2010, Integration, scaling, space-group assignment and post-refinement, Acta Crystallogr. D Biol. Crystallogr., 66, 133, 10.1107/S0907444909047374 · DOI · Paper page
- Kallewaard, 2016, Structure and function analysis of an antibody recognizing all influenza A subtypes, Cell, 166, 596, 10.1016/j.cell.2016.05.073 · DOI · Paper page
- Kreer, 2020, Longitudinal isolation of potent near-germline SARS-CoV-2-neutralizing antibodies from COVID-19 patients, Cell, 182, 843, 10.1016/j.cell.2020.06.044 · DOI · Paper page
- Krissinel, 2007, Inference of macromolecular assemblies from crystalline state, J. Mol. Biol., 372, 774, 10.1016/j.jmb.2007.05.022 · DOI · Paper page
- Kwong, 2012, Human antibodies that neutralize HIV-1: identification, structures, and B cell ontogenies, Immunity, 37, 412, 10.1016/j.immuni.2012.08.012 · DOI · Paper page
- Kwong, 2018, HIV-1 vaccines based on antibody identification, B cell ontogeny, and epitope structure, Immunity, 48, 855, 10.1016/j.immuni.2018.04.029 · DOI · Paper page
- Lefranc, 2009, IMGT, the international ImMunoGeneTics information system, Nucleic Acids Res., 37, D1006, 10.1093/nar/gkn838 · DOI · Paper page
- Liu, 2020, Cross-neutralization of a SARS-CoV-2 antibody to a functionally conserved site is mediated by avidity, Immunity, 53, 1272, 10.1016/j.immuni.2020.10.023 · DOI · Paper page
- Lv, 2020, Structural basis for neutralization of SARS-CoV-2 and SARS-CoV by a potent therapeutic antibody, Science, 369, 1505, 10.1126/science.abc5881 · DOI · Paper page
- McCallum, 2020, Structure-guided covalent stabilization of coronavirus spike glycoprotein trimers in the closed conformation, Nat. Struct. Mol. Biol., 27, 942, 10.1038/s41594-020-0483-8 · DOI · Paper page
- McCoy, 2007, Phaser crystallographic software, J. Appl. Cryst., 40, 658, 10.1107/S0021889807021206 · DOI · Paper page
- Pappas, 2014, Rapid development of broadly influenza neutralizing antibodies through redundant mutations, Nature, 516, 418, 10.1038/nature13764 · DOI · Paper page
- Pettersen, 2004, UCSF chimera—a visualization system for exploratory research and analysis, J. Comput. Chem., 25, 1605, 10.1002/jcc.20084 · DOI · Paper page
- Punjani, 2017, cryoSPARC: algorithms for rapid unsupervised cryo-EM structure determination, Nat. Methods, 14, 290, 10.1038/nmeth.4169 · DOI · Paper page
- Schmidt, 2013, Preconfiguration of the antigen-binding site during affinity maturation of a broadly neutralizing influenza virus antibody, Proc. Natl. Acad. Sci. USA, 110, 264, 10.1073/pnas.1218256109 · DOI · Paper page
- Schramm, 2016, SONAR: a high-throughput pipeline for inferring antibody ontogenies from longitudinal sequencing of B cell transcripts, Front. Immunol., 7, 372, 10.3389/fimmu.2016.00372 · DOI · Paper page
- Suloway, 2005, Automated molecular microscopy: the new Leginon system, J. Struct. Biol., 151, 41, 10.1016/j.jsb.2005.03.010 · DOI · Paper page
- Toelzer, 2020, Free fatty acid binding pocket in the locked structure of SARS-CoV-2 spike protein, Science, 370, 725, 10.1126/science.abd3255 · DOI · Paper page
- Walls, 2020, Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein, Cell, 181, 281, 10.1016/j.cell.2020.02.058 · doi:10.1016/j.cell.2020.02.058 · Paper page
- Winn, 2011, Overview of the CCP4 suite and current developments, Acta Crystallogr. D Biol. Crystallogr., 67, 235, 10.1107/S0907444910045749 · DOI · Paper page
- Wrapp, 2020, Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation, Science, 367, 1260, 10.1126/science.abb2507 · DOI · Paper page
- Wu, 2020, An alternative binding mode of IGHV3-53 antibodies to the SARS-CoV-2 receptor binding domain, Cell Rep., 33, 108274, 10.1016/j.celrep.2020.108274 · DOI · Paper page
- Wu, 2020, A noncompeting pair of human neutralizing antibodies block COVID-19 virus binding to its receptor ACE2, Science, 368, 1274, 10.1126/science.abc2241 · DOI · Paper page
- Yao, 2021, Rational development of a human antibody cocktail that deploys multiple functions to confer Pan-SARS-CoVs protection, Cell Res., 31, 25, 10.1038/s41422-020-00444-y · DOI
- Ye, 2013, IgBLAST: an immunoglobulin variable domain sequence analysis tool, Nucleic Acids Res., 41, 10.1093/nar/gkt382 · DOI · Paper page
- Zhou, 2013, Multidonor analysis reveals structural elements, genetic determinants, and maturation pathway for HIV-1 neutralization by VRC01-class antibodies, Immunity, 39, 245, 10.1016/j.immuni.2013.04.012 · DOI · Paper page
- Zhou, 2015, Structural repertoire of HIV-1-neutralizing antibodies targeting the CD4 supersite in 14 donors, Cell, 161, 1280, 10.1016/j.cell.2015.05.007 · DOI · Paper page
- Zhou, 2020, A pneumonia outbreak associated with a new coronavirus of probable bat origin, Nature, 579, 270, 10.1038/s41586-020-2012-7 · DOI · Paper page
- Zhu, 2014, Antibody structure determination using a combination of homology modeling, energy-based refinement, and loop prediction, Proteins, 82, 1646, 10.1002/prot.24551 · DOI · Paper page
- Zhu, 2020, A novel coronavirus from patients with pneumonia in China, 2019, N. Engl. J. Med., 382, 727, 10.1056/NEJMoa2001017 · DOI · Paper page
Cited by
SARS-CoV-2 501Y.V2 escapes neutralization by South African COVID-19 donor plasma
Wibmer, C. K., Ayres, F., Hermanus, T., Madzivhandila, M., Kgagudi, P., Oosthuysen, B., Lambson, B. E., de Oliveira, T., Vermeulen, M., van der Berg, K., et al. (2021) · Nature Medicine · doi:10.1038/s41591-021-01285-x · Cited by 1,147
Structural and functional ramifications of antigenic drift in recent SARS-CoV-2 variants
Yuan, M., Huang, D., Lee, C.-C. D., Wu, N. C., Jackson, A. M., Zhu, X., Liu, H., Peng, L., van Gils, M. J., Sanders, R. W., et al. (2021) · doi:10.1101/2021.02.16.430500 · Cited by 364
SARS-CoV-2 501Y.V2 escapes neutralization by South African COVID-19 donor plasma
Wibmer, C. K., Ayres, F., Hermanus, T., Madzivhandila, M., Kgagudi, P., Oosthuysen, B., Lambson, B. E., de Oliveira, T., Vermeulen, M., van der Berg, K., et al. (2021) · doi:10.1101/2021.01.18.427166
SARS-CoV-2 B.1.617 Mutations L452R and E484Q Are Not Synergistic for Antibody Evasion
Ferreira, I. A. T. M., Kemp, S. A., Datir, R., Saito, A., Meng, B., Rakshit, P., Takaori-Kondo, A., Kosugi, Y., Uriu, K., Kimura, I., et al. (2021) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiab368 · Cited by 151
Robinson, S. A., Raybould, M. I. J., Schneider, C., Wong, W. K., Marks, C., & Deane, C. M. (2021) · PLOS Computational Biology · doi:10.1371/journal.pcbi.1009675 · Cited by 46
Metadata
- Authors
- Rapp, M., Guo, Y., Reddem, E. R., Yu, J., Liu, L., Wang, P., Cerutti, G., Katsamba, P., Bimela, J. S., Bahna, F. A., Mannepalli, S. M., Zhang, B., Kwong, P. D., Huang, Y., Ho, D. D., Shapiro, L., & Sheng, Z.
- Venue
- Cell Reports
- Publisher
- Elsevier BV
- Published
- 2021-04
- Volume
- 35
- Issue
- 1
- Pages
- 108950
- ISSN
- 2211-1247 (ISSN-L)
- OpenAlex
- W3136200177
- Cited by
- 64
- References
- 34
- FWCI
- 3.70
- Type
- journal article
- Language
- en
- Open access
- gold
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- creativecommons.org/licenses/by-nc-nd/4.0/ (vor)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.